QISSA disruptive leap in non-contrast MR Angiography

Nel mondo, oltre 200 milioni di persone soffrono di malattia arteriosa periferica (PAD).1,2
La controindicazione all'impiego di mdc rende difficile la diagnosi in moltissimi pazienti.
Superate i limiti attuali e migliorate le capacità cliniche con QISS3, tecnica Angio-RM senza mdc completamente nuova.
QISS aiuta a migliorare la sicurezza e la compliance del paziente per ottenere più accuratezza4 e una migliore gestione della malattia, mantenendo la certezza diagnostica degli esami MRA periferici.

La pianificazione e l'esecuzione della CE-MRA richiede competenze di alto livello per prevenire l'In flow venoso e altri artefatti causati, per esempio, da un timing d'iniezione del mezzo di contrasto non ottimale.

Grazie all'esecuzione Set-n-go (Imposta e vai), "QISS provides an easy-to-handle approach for imaging peripheral arteries with little requirements for further adjustments".¹ Inoltre QISS² offre l'opportunità di ridurre di costi operativi anche di 180 dollari per paziente in quanto non si utilizzano consumabili, agenti di contasto e test di laboratorio (GFR).³

Il pacchetto software per Angiografia MR periferica senza mdc è basato sull'imaging Quiescent Interval Single Shot.

• ECG triggered
• Tecnologia 2D non-sottrattiva affidabile
• Esecuzione Set-n-go (software Dot aggiuntivo) per una facile applicazione
• Esportazione di tutte le immagini in un'unica serie (vista combinata, simil-CT)

About 347 million people worldwide have diabetes.¹ In many cases this leads to perihperal artery disease.

"The high prevalance of chronic renal impairment in diabetic patients with PAD and the need for high doses of gadolinium based contrast agents place them at risk for nephrogenic system fibrosis."²

QISS³ provides an accurate non-contrast alternative to CE-MRA for demonstrating clinically significant arterial disease in patients where contrast agents are contraindicated.^2,4 Enhance clinical capabilities with access to latest clinical standards of care and improve patient safety with the reduced need for CE-MRA.

"QISS MRA should become the non-contrast MRA technique of choice in patients with renal dysfunction."⁵

Maria Carr, Research Technologist
Northwestern University Feinberg School of Medicine
Chicago, US

High Acceleration Quiescent-Interval Single Shot Magnetic Resonance Angiography at 1.5 and 3T

Non-Contrast-Enhanced ECG-Gated Quiescent Interval Single Shot MR Angiography of the Lower Extremities at 3 Tesla: a Case Report

Quiescent-Intervall Single-Shot Magnetic Resonance Angiography

QISS Non-Contrast MR Angiography: A study of Three Cases with Peripheral Vascular Disease

Peripheral arterial disease in patients with diabetes.

Quiescent-Interval Single-Shot Unenhanced Magnetic Resonance Angiography of Peripheral Vascular Disease: Technical Considerations and Clinical Feasibility

Peripheral arterial disease in a symptomatic diabetic population: prospective comparison of rapid unenhanced MR angiography (MRA) with contrast-enhanced MRA.

Evaluation of peripheral arterial disease with nonenhanced quiescent-interval single-shot MR angiography.

Nonenhanced ECG-gated quiescent-interval single-shot MRA (QISS-MRA) of the lower extremities: comparison with contrast-enhanced MRA.

Comparison of quiescent inflow single-shot and native space for nonenhanced peripheral MR angiography.

Nonenhanced peripheral MR-angiography (MRA) at 3 Tesla: evaluation of quiescent-interval single-shot MRA in patients undergoing digital subtraction angiography.

Evaluating Peripheral Arterial Disease With Unenhanced Quiescent-Interval Single-Shot MR Angiography at 3T

Nonenhanced ECG-Gated Quiescent-Interval Single Shot MRA: Image Quality and Stenosis Assessment at 3 Tesla Compared With Contrast-Enhanced MRA and Digital Subtraction Angiography

ECG-gated quiescent-interval single-shot MR angiography of the lower extremities: initial experience at 3 T.

Non-contrast-enhanced MR angiography at 3 Tesla in patients with advanced peripheral arterial occlusive disease.

Sequence comparison for non-enhanced MRA of the lower extremity arteries at 7 Tesla